Loading...
•
Mar 31, 2020
Editas Q1 2020 Earnings Report
Editas reported first quarter results, initiated patient dosing in BRILLIANCE Phase 1/2 trial of EDIT-101 for LCA10, and remained on track to file IND for EDIT-301 for sickle cell disease by the end of 2020.
Key Takeaways
Editas Medicine reported its Q1 2020 results, highlighting the initiation of patient dosing for EDIT-101 and progress towards filing an IND for EDIT-301. The company's cash, cash equivalents, and marketable securities totaled $415 million as of March 31, 2020.
Patient dosing initiated in BRILLIANCE Phase 1/2 trial of EDIT-101 (AGN-151587) for LCA10.
Company is on track to file IND for EDIT-301 for sickle cell disease by end of 2020.
IND-enabling studies initiated for EDIT-201 allogeneic NK cell medicine for solid tumors.
Cash, cash equivalents, and marketable securities of $415 million as of March 31, 2020.
Editas
Editas
Forward Guidance
Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world.
Positive Outlook
- Advancing an entirely new class of medicines to the clinic with the first ever administration of EDIT-101.
- Expansion of clinical programs through an expected IND filing for EDIT-301.
- EDIT-301 is a potentially best-in-class treatment for sickle cell disease and beta-thalassemia.
- Completing dosing of the adult low-dose cohort of EDIT-101.
- Dosing at least one patient of the adult mid-dose cohort of EDIT-101 by the end of 2020.
Challenges Ahead
- Potential business interruptions due to the COVID-19 outbreak.
- Delaying to 2021 the declaration of a development candidate for an experimental medicine to treat autosomal dominant retinitis pigmentosa 4 due to interruptions from the COVID-19 outbreak.
- Uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials and clinical development of the Company’s product candidates.
- Availability and timing of results from pre-clinical studies and clinical trials.
- Whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials.